Cargando…
Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Singapore
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520881/ https://www.ncbi.nlm.nih.gov/pubmed/34499262 http://dx.doi.org/10.1007/s10147-021-02018-3 |
| _version_ | 1784584774988333056 |
|---|---|
| author | Sekine, Masayuki Enomoto, Takayuki Watanabe, Yoh Katabuchi, Hidetaka Yaegashi, Nobuo Aoki, Daisuke |
| author_facet | Sekine, Masayuki Enomoto, Takayuki Watanabe, Yoh Katabuchi, Hidetaka Yaegashi, Nobuo Aoki, Daisuke |
| author_sort | Sekine, Masayuki |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8520881 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Singapore |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85208812021-10-29 Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer Sekine, Masayuki Enomoto, Takayuki Watanabe, Yoh Katabuchi, Hidetaka Yaegashi, Nobuo Aoki, Daisuke Int J Clin Oncol Correction Springer Singapore 2021-09-09 2021 /pmc/articles/PMC8520881/ /pubmed/34499262 http://dx.doi.org/10.1007/s10147-021-02018-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Sekine, Masayuki Enomoto, Takayuki Watanabe, Yoh Katabuchi, Hidetaka Yaegashi, Nobuo Aoki, Daisuke Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer |
| title | Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer |
| title_full | Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer |
| title_fullStr | Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer |
| title_full_unstemmed | Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer |
| title_short | Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer |
| title_sort | correction to: the efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520881/ https://www.ncbi.nlm.nih.gov/pubmed/34499262 http://dx.doi.org/10.1007/s10147-021-02018-3 |
| work_keys_str_mv | AT sekinemasayuki correctiontotheefficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT enomototakayuki correctiontotheefficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT watanabeyoh correctiontotheefficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT katabuchihidetaka correctiontotheefficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT yaegashinobuo correctiontotheefficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer AT aokidaisuke correctiontotheefficacyandsafetyprofileof2weeklydosingofbevacizumabcontainingchemotherapyforplatinumresistantrecurrentovariancancer |